师资队伍

吴明媛

副研究员

 

电话:021-34204760
邮箱:wumingyuan@sjtu.edu.cn

吴明媛 博士,副研究员,主要研究方向是生物大分子药物和肿瘤免疫治疗。2005年毕业于苏州大学医学院,获免疫学专业博士学位。2012年赴德国萨尔大学血液移植研究所访问。曾主持“863” 子课题项目、国家自然基金项目和转化医学等项目,参与完成多项国家自然基金、国家支撑项目和上海市科委等项目,发表学术论文20余篇、申请专利2项。曾获得上海市药学会科技奖三等奖、黑龙江省科技厅科技进步奖三等奖
1 蛋白类药物和纳米抗体药物的研制;
2 肿瘤的免疫治疗;
3 造血干细胞和免疫细胞的分化调控。
1. Shuai Hao, Shuyi Xu, Liangzhu Li, Yaxian Li, Meiqi Zhao, Junsheng Chen, Shunying Zhu, Yueqing Xie, Hua Jiang, Jianwei Zhu*, Mingyuan Wu*. Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PDL1 and CXCR4. BMC Cancer. 2022, 22:1092.
2. Haoneng Tang, Yong Ke, Lei Wang, Mingyuan Wu*, Tao Sun*, Jianwei Zhu *.Recombinant Decoy Exhibits Broad Protection against Omicron and Resistance Potential to Future Variants. Pharmaceuticals. 2022, 15:1002.
3. Tang H, Ke Y, Liao Y, Bian Y, Yuan Y, Wang Z, Yang L, Ma H, Sun T, Zhang B*,Zhang X*, Wu M*, Zhu J*. Mutational Escape Prevention by Combination of FourNeutralizing Antibodies that Target RBD Conserved Regions and Stem Helix. Virologica Sinica. Received, 2022, 10
4. Mingyuan Wu#, Sonja Moldenhauer#, Matthias Duetsch, Thomas Scheffel, Rainer Hellweg, Andreas Holloschi, Frank Rainer Abel, Wei Han, Anja Moldenhauer*. Acupuncture in Patients with Spinal Cord Injuries: Mobilization of Potential Neuroprogenitors and Clinical Outcome in a Case Series. International Journal of Chinese Medicine. 2021, 5:29.
5. Wu Mingyuan#, Moldenhauer Sonja#, Duetsch Matthias, Scheffel Thomas, Hellweg Rainer, Holloschi Andreas, Abel Frank Rainer, Han Wei, Moldenhauer Anja*. Acupuncture-induced differentiation of stem cells into neuron-like cells in patients with spinal cord injuries. Acupuncture in Medicine. 2019, 37:136.
6. Deng Shaorong, Deng Qing, Zhang Yingjie, Ye Hao, Yu Xiaolan, Zhang Yang, Han Grace Y Q, Luo Ping, Wu, Mingyuan, Yu Yan*, Han, Wei*. Non-platelet-derived CXCL4 differentially regulates cytotoxic and regulatory T cells through CXCR3 to suppress the immune response to colon cancer. Cancer Letters.2019,443:1.
7. Hongjing Yu#, Mingyuan Wu#, Bin Wen, Ningyun Sun, Di Xiang, Jing Zhang, Shunying Zhu, Shunyan Weng, Yan Yu, Wei Han*. Antagonist effect of Interleukin 1 receptor on normal thymopoiesis and thymus toxicity of 5-azacytidine in mouse. Am J Transl Res. 2016, 8:1237.
8. Yang Zhang, Jing Gao, Xia Wang, Shaorong Deng, Hao Ye, Wen Guan, Mingyuan Wu, Shunying Zhu, Yan Yu*, Wei Han*. CXCL4 mediates tumor regrowth after chemotherapy by suppression of antitumor immunity. Cancer Biol Ther. 2015,16:1775.
9. Jing Gao#, Mingyuan Wu#, Jin Gao, Xia Wang, Yang Zhang, Shunying Zhu, Yan Yu*, and Wei Han*. Generation and Characterization of a New Monoclonal Antibody Against CXCL4. Monoclonal antibodies in immunodiagnosis and immunotherapy. 2015, 34:110.
10. Qian L#, Xiang D, Zhang J, Zhu S, Gao J, Wang X, Gao J, Zhang Y, Shen J, Yu Y, Han W*, Wu M*. Recombinant human interleukin-1 receptor antagonist reduces acute lethal toxicity and protects hematopoiesis from chemotoxicity in vivo. Biomed Pharmacother. 2013, 67:108.
11. Zhao M#, Gao J, Zhu S, Qian L, Wang X, Gao J, Zhang Y, Yu Y*, Han W*, Wu M*. Characterization of activin A in the culture of primitive human umbilical cord blood hematopoietic cells. Biomed Pharmacother. 2012, 66:603.
1. 生物药物体内评价体系的建立及其应用,国内企业合作,2022-2025年,25万元,主持,在研。
2. 双特异性纳米抗体anti CXCR4&PD-L1 抑制胰腺癌的药效学研究,上海交大转化医学研究院开放课题,2020-2022年,20万元,主持,在研。
3. PODXL靶向单抗RM1-96在胃癌PDTX模型中的疗效评价及其抗肿瘤分子机制的研究,医工交叉基金,20万,合作主持,在研。
4. 生物药物体内评价体系的建立及其应用,国内企业合作,2018-2020年,55万元,主持,结题。
5. 抗新型冠状病毒2019-nCov单克隆抗体的研究及制备,科技创新专项-医工交叉研究基金,2020-2021,100万,参与,结题。
6. 趋化因子CXCL4抑制肿瘤细胞免疫的分子机制研究,国家自然科学基金,2017.01-2020.12,60万元,参与,结题。
7. 重组人白细胞介素-1受体拮抗剂预防化疗后骨髓损伤的药效学研究,国家自然科学基金项目,2010-2012年,20万,主持,结题。
8. 华东干细胞库及临床级hESC建系技术平台,国家科技部支撑计划, 2007-2009年,260万,子课题负责人,结题。
9. 人脐带血造血干细胞扩增方案临床前研究,上海市科委,2007-2009年,16万,参加,结题。

网站声明|友情链接|联系我们|返回旧版

地址:上海市东川路800号 邮编:200240
© 2020 上海交通大学药学院